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Abstract
Small cell carcinomas (SCCs) are aggressive neoplasms commonly associated with a pulmonary origin. However, albeit rare,
extrapulmonary SCC can occur in a variety of sites with an incidence in North America approximated to be 0.1% to 0.4%.
Among these sites, approximately 10% of extrapulmonary SCC cases occur in the prostate and are associated with a poor
mortality with a median survival of 10 months. Because of the rarity of the prostatic SCC, there is no formal treatment
protocol. In this case report, we present a patient who was diagnosed with SCC in the prostate as primary origin. Adjuvant
concurrent chemoradiotherapy was started, which he is tolerating so far. While the management of metastatic disease is
well documented with the use of chemotherapy, specific data on nonmetastatic disease is lacking. As some studies suggest, a
combined surgical and chemotherapeutic approach is helpful in localized disease. In our case, this approach has led to a good
clinical outcome in a disease that does not usually allow such results.
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Introduction
Small cell carcinomas (SCCs) are aggressive neoplasms commonly associated with a pulmonary origin. However, albeit
rare, extrapulmonary SCC (EPSCC) can occur in a variety of
sites with an incidence in North America approximated to be
0.1% to 0.4%.1 Among these sites, approximately 10% of
EPSCC cases occur in the prostate2,3 and are associated with a
poor survival, with a median survival of 10 months.3,4 Because
of the rarity of the prostatic SCC, there is no formal treatment
protocol. Current treatment is based on studies of pulmonary
SCC, using a combined chemoradiotherapeutic approach with
radical prostatectomy as an adjunct in only a few selected
cases.5-8 With the poor outcome of this aggressive subtype of
prostate cancer, further studies can help improve treatment
outcomes. Here, we present a case of limited-stage pure SCC
of the prostate treated with a total cystoprostatectomy and
adjuvant chemoradiotherapy.

Case Report
A 60-year-old Caucasian male presented with episodes of
urinary retention, a normal digital rectal examination, and
no other urinary symptoms. His past medical history was
significant for a high-grade T1 transitional cell carcinoma of
the bladder 1 year prior, as well as another T1 transitional
cell carcinoma of the bladder 7 months after the first tumor

was diagnosed. For the first tumor, he successfully underwent transurethral resection of the tumor and 6 cycles of
intravesical bacillus Calmette-Guerin (BCG) immunotherapy. The same treatment plan was given for his second
tumor, but he developed BCG-osis after the fourth cycle. He
underwent close follow-up by his urologist with abdominal/
pelvic computed tomography (CT) scans and urine cytology. Three months later, around the onset of his urinary
retention, imaging showed thickening of his bladder wall,
and urine cytology was positive for malignancy. Furthermore,
on bimanual examination, a firm, but moveable mass was
palpated. With these new findings, the patient was recommended cystoscopy with transurethral resection of the prostate to investigate a suspected recurrence of bladder cancer
and to provide relief of his obstructive symptoms. The
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Figure 1. The tumor is composed of cells with hyperchromatic
nuclei, no nucleoli, scant cytoplasm, and nuclear molding, with
numerous mitoses (hematoxylin-eosin, 400×).

Figure 2. The tumor has neuroendocrine features as shown by
positivity with antibodies to CD56 (400×).

procedure relieved not only the patient’s urinary retention
but also revealed a fleshy mass occupying the right lobe of
the prostate and no bladder masses. The pathologist reported
the transrectal ultrasound-guided prostate biopsy to be consistent with a small cell neuroendocrine carcinoma. Highpower evaluation (400×) demonstrated tumor cells with
hyperchromatic nuclei, no nucleoli, scant cytoplasm, and
nuclear molding, with numerous mitoses (Figure 1). The
tumor has neuroendocrine features as shown by positivity
with antibodies to CD5 (Figure 2) and synaptophysin
(Figure 3).
Immunohistochemical stains were found to be positive
for P53, CK7, and AE1/AE3 (Figures 4-6) but negative for
staining with antibodies to chromogranin A, CK20, PSA,
uroplakin III, GATA-3, and LCA (data not shown).
The specimen was also compared with the patient’s previous bladder biopsy and determined to be morphologically dissimilar. Further staging workup was obtained with positron
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Figure 3. The tumor has neuroendocrine features as shown by
positivity with antibodies to synaptophysin (400×).

Figure 4. p53 mutation is shown by positive nuclear staining
with antibody to p53 (400×).

Figure 5. The tumor is a carcinoma as evidenced by positivity
with antibodies to CK7 (400×).
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Figure 6. The tumor is a carcinoma as evidenced by positivity
with antibodies to cytokeratin AE1/AE3 (400×).

emission tomography (PET)/CT scan and with magnetic resonance imaging of the pelvis–neither of which revealed obvious lymphadenopathy or extraprostatic spread. Considering
the localized nature of the tumor, the patient underwent a
robotic-assisted total cyst prostatectomy with lymph node
sampling of the right and left obturator lymph nodes. Final
pathology report confirmed a submucosal small cell neuroendocrine carcinoma in the prostatic base, 3.5 cm at its greatest
dimension, with involvement of the bladder neck and trigone
area. One of the 2 lymph nodes were positive for metastatic
carcinoma, and final pathologic staging was determined to be
T3aN1M0. He underwent adjuvant concurrent chemoradiotherapy with cisplatin/etoposide. The patient completed 4
cycles and at last follow-up, 12 months after diagnosis, is tolerating the treatment well with negative CT imaging for
recurrence.

Discussion
Although the prostate is one of the common site for
EPSCC, it is a rare prostatic malignancy.2,3,9 Of these
cases, only about 35% are pure SCC of the prostate, with
the rest having concurrent adenocarcinomatous components,5 but it is currently unknown whether this pathological difference affects the management or prognosis.
SCC of the prostate is reported to be more prevalent in
the elderly with over 70% of patients being over the age
of 65.10 Unlike prostate adenocarcinomas, most patients
with SCC of the prostate are symptomatic. The most frequently reported symptoms are obstructive symptoms,
pressure-related neurological symptoms, or constitutional symptoms, with 10% of cases present with paraneoplastic symptoms.9,11 Depending on the tumor
involvement, other clinical features include bone pain,
hydronephrosis, abdominal pain, hematochezia, and
hematuria. Imaging of the pelvis is generally nonspecific

and serum prostate-specific antigen levels often remain
within normal ranges.5 Ultimately, SCC of the prostate is
diagnosed by pathological analysis of morphology and
immunohistochemistry.3,5,11
Much of our current treatment approach to prostatic
SCC are extrapolated from studies on the management of
pulmonary SCC. In the limited studies available on the
management of prostatic SCC, the recommended first-line
treatment is chemotherapy with a combined use of cisplatin and etoposide because of its comparatively higher efficacy rate.5,6,11 However, most of these cases are patients
with metastatic or extensive-stage prostatic SCC, the
more common presentation of the tumor. With respect to
nonmetastatic or limited-stage prostatic SCC, a couple of
studies recommend prostatectomy with adjuvant chemotherapy, but this approach is controversial.2,5,12 Most studies report using chemotherapy as the first-line treatment
regardless if the tumor is metastatic or not; hence, it is
difficult to properly assess the efficacy of a surgical therapy with adjuvant chemotherapy. Several studies have
reported that prostatectomy alone is not effective.5,8,13 In
these localized tumors, as in our case, it would be logical
to remove the tumor to potentially prevent possible metastases and use adjuvant chemotherapy to treat possible
occult metastases.

Conclusion
SCC of the prostate is an aggressive tumor that is associated
with a high mortality. While the management of metastatic
disease is well documented with the use of chemotherapy,
specific data on nonmetastatic disease are lacking. As some
studies suggest, a combined surgical and chemotherapeutic
approach is helpful in localized disease. In our case, this
approach has led to a good clinical outcome in a disease that
does not usually allow such results.
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